Viral Vectors & Plasmid DNA Manufacturing

Viral Vectors & Plasmid DNA Manufacturing Market Value to Cross US$ 1.3 Bn by 2027 Viral Vectors & Plasmid DNA Manufacturing Market - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2020 - 2027

Share This Article

[150+ Pages Report] The viral vectors & plasmid DNA manufacturing market size in terms of value is projected to reach $ 1.3 billion by 2027, at a CAGR of 14.08% between 2020 and 2027, according to a 2021 study by Precedence Research, the Canada based market insight company.

The study provides the overall revenue of the global viral vectors & plasmid DNA manufacturing market from 2016 to 2027, considering 2020 as the base year and 2027 as the forecast year.

The global viral vectors & plasmid DNA manufacturing market research report gives a brief summary of definitions, size analysis, and place of production, sales, applications, types, and major players/key vendors of the viral vectors & plasmid DNA manufacturing industry. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post-COVID-19 marketplace. This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

We customize your report according to your research need. REQUEST SAMPLE OR CUSTOMIZED COPY OF THIS REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1012

Report Highlights

  • By Vector Type, in 2019, AAV dominated the market with around 22.83% share in terms of revenue of the total market. Lentivirus is projected to grow at highest CAGR of 23.27% during forecast period and anticipated to attain a market share of 17.41% in 2027.
  • The global market for the Plasmid DNA was valued at USD 83.5 million in 2019 and is expected to reach USD 407.4 million by 2027.
  • By Disease Type, in 2019, cancer dominated the market with around 55.32% share in terms of revenue of the total market. This growth is credited to the rising cancer incidence across the globe. Cancer is also projected to grow at highest CAGR of 22.32% during forecast period.
  • By Application Type, in 2019, gene therapy dominated the market with around 37.23% share in terms of revenue of the total market. The global market for the Antisense &RNAi was valued at USD 111.5 million in 2019 and is expected to reach USD 543.4 million by 2027.
  • By End-User, in 2019, Biopharmaceutical & Pharmaceutical Companies dominated the market with around 67.45% share in terms of revenue of the total market. Biopharmaceutical & Pharmaceutical Companies is projected to grow at highest CAGR of 22.27% during forecast period.
  • Europe Viral Vectors & Plasmid DNA Manufacturing market was estimated at USD 92.7 million in 2019 and is projected to reach value USD 435.2 million by 2027.
  • Asia Pacific Viral Vectors & Plasmid DNA Manufacturing market was estimated at USD 56.2 million in 2019 and is projected to reach value USD 294.5 million by 2027.

Growth Factors

Viral vectors have become ideal choice for gene transferdue to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer. Growing pervasiveness of target disorders and diseases, the accessibility of funding for gene therapy development, current research into viral vector-based cell and gene therapies and efficacy of viral vectors in gene therapy delivery are together supporting the market growth. Unexploitedlatent in emergent markets is projected to provideworthwhile growth opportunities for participants in this market. Furthermore, groundbreaking development in the vaccinology is fuelling the demand of these vectors to greater extent. Great amount of clinical and preclinical studies assessing the prospective of vectors in these cutting-edge therapies haveexhibitedfavorable results. As a result of this,several investors are attracted towards this area which is making plasmid and viral vector manufacturing market avigoroussector of investment. Further, it is inspiringfortunate funding activities from both the public and private sectors.

Report Scope of the Viral Vectors & Plasmid DNA Manufacturing Market

Report Coverage Details
Market Size USD 1.3 Billion by 2027
Growth Rate CAGR of 14.08% From 2020 to 2027
Base Year 2020
Historic data 2017 to 2020
Forecast Period 2021 to 2027
Segments Covered Vector Type, Application, Workflow, End-User, Disease
Regional Scope Asia Pacific, North America, Europe, Latin America, Middle East and Africa
Companies Mentioned BioReliance, Aldevron, Eurogentec, Cobra Biologics, Lonza, MassBiologics, FUJIFILM Diosynth Biotechnologies, WuXiAppTec

Market Dynamics:

Drivers

  • Rising prevalence of cancer and rare genetic diseases
  • Growing research & development of gene therapies in cancer treatment

Market Restraints

  • Challenges in executing gene therapies
  • High cost associated with gene therapies

Opportunities

  • Investment and collaboration in cell and gene therapy sector
  • Increase in demand for synthetic genes

Gene therapy is an experimental treatment that comprises incorporating genetic material inside a person’s cells to stopor fight a particular disease. Researchers are studying gene therapy for several diseases including hemophilia, cancer, Parkinson’s disease, severe combined immuno-deficiencies, HIV, via numerous dissimilar methods. A gene can be carried to a cell with the help of a carrier known as a vector. Viruses are the most generalkinds of vectors used in gene therapy. Since last few years, several non-viral and viral vectors have been standardized and enhanced.

At present, the much wide spread viral vectors utilized for gene therapies are those based on lentivirus, retrovirus, adenovirus, and AAV vectors. These correspondingly form 8%, 16%, 20%, and 8% of the clinical trialsof active gene therapy. Likewise, plasmid DNA has appeared as the most frequently preferred vectors amid non-viral gene delivery tools. Further, it finds application in production and development of DNA vaccines and viral vectors. There is growing demand for practical manufacturing solutions for viral vectors that can be freely scaled and boosted. This is because gene and cell therapies possess latent to quickly advance via clinical trials to commercialization.With the help of ongoing efforts, several organizations are respectivelyexecutingand developing state-of-the-art solutions intended to scale-up for viral vector manufacturing and speed up process development.

Global Market Revenue (USD Million) and Growth Rate Comparison by Workflow (2016-2027)

Workflow 2016 2019 2027 CAGR % (2020-2027)
Upstream Processing 94.60 165.45 770.72 21.27 %
Downstream Processing 145.60 261.13 1,301.65 22.30 %
Total 240.20 426.58 2,072.36 21.91 %

Top Players Contending in the Market:

The key companies are aiming towards advanced innovations and are predictable to dominate the target market. Foremost players inspiring in the global viral vectors & plasmid DNA manufacturing market are as follows:

  • Novasep
  • Aldevron
  • MerckWaismanBiomanufacturing
  • Creative Biogene
  • The Cell and Gene Therapy Catapult
  • Cobra Biologics
  • uniQure N.V.
  • Addgene
  • FUJIFILM Holdings Corporation
  • Oxford Biomedicaplc
  • Takara Bio Inc.

Market Segmentation

By Vector Type

  • Adenovirus
  • Plasmid DNA
  • Lentivirus
  • Retrovirus
  • AAV
  • Others

By Application

  • Gene Therapy
  • Antisense &RNAi
  • Cell Therapy
  • Vaccinology

By Workflow

  • Upstream Processing
    • Vector Recovery/Harvesting
    • Vector Amplification & Expansion
  • Downstream Processing
    • Fill-finish
    • Purification

By End-User

  • Biopharmaceutical and Pharmaceutical Companies
  • Research Institutes

By Disease

  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Others

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Some of the key highlights of the report are:

  • Market Demand Outlook – The report offers refined forecasts on potential growth prospects for the market. Based on data derived after thorough research by a team of expert analysis, Precedence Research presents the most precise rate of growth for the market for the assessment period starting from 2021 – 2030.
  • Supply Chain Analysis – The purpose of the survey is to help companies identify potential scope for supply chain expansion. The study also presents analysis of unprecedented threats.
  • Competitive Landscape Analysis – Some of the leading companies operating in the viral vectors & plasmid DNA manufacturing market are profiled in the market study. The report also underscores winning strategies adopted over the last few years and gauges impact of the same on growth trajectory exhibited by the market over the last few years.

Why should you invest in this report?

If you are aiming to enter the global viral vectors & plasmid DNA manufacturing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for viral vectors & plasmid DNA manufacturing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2020-2027 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Purchase This Premium Research Report @ https://www.precedenceresearch.com/checkout/1012

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defence, among different ventures, present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →